Menu
Back to Journals » ClinicoEconomics and Outcomes Research » Volume 17
ISSN: 1178-6981
- View all (947)
- Volume 17, 2025 (38)
- Volume 16, 2024 (62)
- Volume 15, 2023 (67)
- Volume 14, 2022 (61)
- Volume 13, 2021 (90)
- Volume 12, 2020 (70)
- Volume 11, 2019 (71)
- Volume 10, 2018 (77)
- Volume 9, 2017 (77)
- Volume 8, 2016 (73)
- Volume 7, 2015 (64)
- Volume 6, 2014 (53)
- Volume 5, 2013 (59)
- Volume 4, 2012 (41)
- Volume 3, 2011 (19)
- Volume 2, 2010 (16)
- Volume 1, 2009 (9)
Archive: Volume 17, 2025
Healthcare Costs and Treatment Patterns of Triplet Therapies in Relapsed/Refractory Multiple Myeloma: Real World Evidence from Italy
Perrone V, Leogrande M, Giacomini E, Cappuccilli M, Degli Esposti L
ClinicoEconomics and Outcomes Research 2025, 17:495-505
Published Date: 19 July 2025
Adding Tolvaptan in the Inpatient Treatment for Patients with Heart Failure and Hyponatremia: Budget Impact Analysis in Thailand
Permsuwan U, Leemasawat K, Arunmanakul P
ClinicoEconomics and Outcomes Research 2025, 17:485-494
Published Date: 16 July 2025
Evaluating the Economic Impact of Diabetes Mellitus: A Hospital-Centric Cost Analysis in Hail, Saudi Arabia
Alshammari AM, Elnaem MH, Ong SC
ClinicoEconomics and Outcomes Research 2025, 17:473-484
Published Date: 15 July 2025
Comparative Cost Analysis for Direct Medical Costs of Protocol Administration of Non-Small Cell Lung Cancer Treatment Regimens in Curative Intent: A Micro-Costing Study in Jordan
Madae’en SS, Salem AA, Ararawi NS, Ramzi EJ, Aloueedat RF, Saabenh AM, Allouzi DA, Abuoudeh RH, Hnaif OE, Musa LM, Alshdaifat SH, Al-Tanashat AJ, Almasa’afeh HY, Abuallaban SM
ClinicoEconomics and Outcomes Research 2025, 17:455-471
Published Date: 12 July 2025
Medicare Savings for Seizure Drugs by Adopting the Mark Cuban Cost Plus Drug Company Model
Smith T, Young A, O’Brien C, Duncan J, Rashid M, Magee T, Fitzgerald K, Vassar M
ClinicoEconomics and Outcomes Research 2025, 17:447-453
Published Date: 18 June 2025
The Economic Burden of Patients with Diabetic Peripheral Neuropathic Pain Based on a Real-World Study in China
Wang R, Xuan DD, Xuan J, Dai D, Ye X, Hu X
ClinicoEconomics and Outcomes Research 2025, 17:437-446
Published Date: 13 June 2025
The Social Cost of Nasal Sequelae in Patients with Cleft Lip and Palate in a Peruvian University Dental Clinic
Córdova-Aguilar A, Ramos W, Blanco-Victorio DJ, López-Ramos RP, Best Bandenay PY, Castañeda Saldaña E, De La Cruz-Vargas JA
ClinicoEconomics and Outcomes Research 2025, 17:429-436
Published Date: 9 June 2025
Time-Driven Activity-Based Costing for Cervical Myelopathy Surgery: A Step Towards Total Episode Costs
Keppetipola KM, Leibold A, Trivedi J, Kabani AS, Sarikonda A, Self DM, Isch EL, Glener S, Prasad S, Jallo J, Heller JE, Harrop J, Vaccaro AR, Sivaganesan A
ClinicoEconomics and Outcomes Research 2025, 17:419-428
Published Date: 3 June 2025
Evaluating the Fiscal Impact of Antiretroviral Therapy for the Management of HIV in the United States 1987–2023
Paquete AT, Mordi U, Jarrett J, Thaliffdeen R, Chaudhari P, Connolly MP, Kotsopoulos N, Sullivan PS
ClinicoEconomics and Outcomes Research 2025, 17:407-418
Published Date: 28 May 2025
Health Economics Evaluation of Bictegravir/Emtricitabine/Tenofovir for a First-Line Treatment of HIV-1 Infection in China
Wang W, Zhou D, Zhou K, Zhang D, Li H, Zhang H, Jiang X, Wang R, Wang X, Tang W
ClinicoEconomics and Outcomes Research 2025, 17:393-406
Published Date: 23 May 2025
Budget Impact of Shifting the Treatment Setting of Unresectable Liver Metastases Associated with Primary Colorectal Cancer Using Y-90 Resin Microspheres from the Outpatient Hospital to the Office-Based Laboratory
Sperling DC, Wallace K, von Oppen N, Weintraub JL
ClinicoEconomics and Outcomes Research 2025, 17:387-392
Published Date: 8 May 2025
Cost-Effectiveness of a Community First Responder System for Out-of-Hospital Cardiac Arrest in Poland
Jaskuła J, Medic G, Verma S, Maurer J, Kooy TA, Greef BD
ClinicoEconomics and Outcomes Research 2025, 17:375-386
Published Date: 2 May 2025
Comprehensive Insights into the Economic Burden of Rheumatoid Arthritis in Latin America: A Systematic Literature Review of Regional Perspectives
Maldonado-Restrepo AI, Acelas-Gonzalez GE, Rodríguez-Vargas GS, Rodriguez-Linares P, Gonzalez-Rodriguez JL, Rojas-Villarraga A, Santos-Moreno P
ClinicoEconomics and Outcomes Research 2025, 17:349-373
Published Date: 17 April 2025
A Cost-Effectiveness Analysis of Mosunetuzumab vs Tisagenlecleucel for Treatment of Third- or Higher-Line (3L+) Relapsed or Refractory (R/R) Follicular Lymphoma (FL) in Italy
Luminari S, Pinto A, Puccini B, D’Arpino A, Omodeo Salè E, Bellone M, Pradelli L, Sabinot A
ClinicoEconomics and Outcomes Research 2025, 17:335-348
Published Date: 16 April 2025
Cost-Minimization Analysis and Budget Impact Analysis About Subcutaneous Natalizumab in Relapsing-Remitting Multiple Sclerosis in Italy
Prosperini L, Pradelli L, Santoni L, Perini D, Cottone S, Vercellino M
ClinicoEconomics and Outcomes Research 2025, 17:315-333
Published Date: 11 April 2025
Clinical and Economic Burden of Managing Patients with Sickle Cell Disease Receiving Frequent Red Blood Cell Transfusions in the United States
Udeze C, Jerry M, Evans KA, Li N, Jain S, Andemariam B
ClinicoEconomics and Outcomes Research 2025, 17:303-313
Published Date: 11 April 2025
Economic Impact of Elranatamab for Treatment of Patients with Relapsed or Refractory Multiple Myeloma
Shah B, Sandin R, Liu Y, Bobolts LR, Hu Y, Mol I, Schepart A, Hughes DM, Hart J, Hlavacek P
ClinicoEconomics and Outcomes Research 2025, 17:289-302
Published Date: 8 April 2025
The Impact of Obesity-Related Complications on Healthcare Costs – Outcomes of a Pharmacoeconomic Weight Loss Model
Yilmaz ES, Malhan S, Gurser B, Gogas Yavuz D
ClinicoEconomics and Outcomes Research 2025, 17:277-287
Published Date: 5 April 2025
Cost-Effectiveness of Oral Nutritional Supplements in Malnourished or at Risk of Disease-Related Malnutrition Cancer Patients in North Macedonia
Kapedanovska Nestorovska A, Sterjev Z
ClinicoEconomics and Outcomes Research 2025, 17:265-276
Published Date: 26 March 2025
Healthcare Resource Utilization and Cost Comparison Between Palbociclib, Abemaciclib, and Ribociclib Among Patients with HR+/HER2− Metastatic Breast Cancer
Pluard TJ, Sandin R, Parikh RC, Ward MA, Stansfield L, Nham T, Esterberg E, Cha-Silva AS, Shah B
ClinicoEconomics and Outcomes Research 2025, 17:247-264
Published Date: 26 March 2025
The Burden of Obesity in Saudi Arabia: A Real-World Cost-of-Illness Study
Nagi MA, Almalki ZS, Thavorncharoensap M, Sangroongruangsri S, Turongkaravee S, Chaikledkaew U, Alqahtani AM, AlSharif LS, Alsubaihi IA, Alzarea AI, Alsultan MM
ClinicoEconomics and Outcomes Research 2025, 17:233-246
Published Date: 21 March 2025
Cost-Effectiveness Analysis of Ofatumumab versus Teriflunomide for Relapsing-Remitting Multiple Sclerosis: A 10-Year Markov Model
Almalki ZS, Alshammari MM, Almazrou SH, Alqahtani OAA, Alkhayat MR, Alnemari SF, Mukhemair HS, Alkredeas SM, Alsuhibani AA, Asiri BY, Alalawi TN, Alahmari AK, Alotaibi FO
ClinicoEconomics and Outcomes Research 2025, 17:217-232
Published Date: 20 March 2025
Patient Experiences with the Impacts of Multiple Sclerosis & Disease-Modifying Therapies
Talente B, Finseth LT, Blake N, Costello K, Schmidt H, Vandigo J, Oehrlein EM
ClinicoEconomics and Outcomes Research 2025, 17:199-215
Published Date: 15 March 2025
The Budget Impact of Cangrelor in the UK for the Treatment of Out-of-Hospital Cardiac Arrest Patients Who Require Percutaneous Coronary Intervention
Modi B, Cain R, Stork R, Barwood C, Tarpey G, Colucciello A
ClinicoEconomics and Outcomes Research 2025, 17:189-197
Published Date: 15 March 2025
Economic Burden of Intravenous Decitabine Administration in Patients Affected by Acute Myeloid Leukemia Ineligible for Induction Chemotherapy and Impact of Oral Formulation Introduction: A Micro-Costing Study in Italy
Di Costanzo A, Loreto L, Vassallo C, Fiorentino F
ClinicoEconomics and Outcomes Research 2025, 17:171-187
Published Date: 13 March 2025
Cost-Effectiveness Analysis for Managing Diabetic Foot Ulcer (DFU) in USA: Platelet-Rich Plasma (PRP) vs Standard of Care (SoC)
Russo S, Landi S, Simoni S
ClinicoEconomics and Outcomes Research 2025, 17:157-169
Published Date: 8 March 2025
Real World Evidence on Hormone Receptor Positive and Human Epidermal Growth Factor Receptor 2 Negative Metastatic Breast Cancer in Italy: Insights From 2017 to 2021 Data
Perrone V, Leogrande M, Cappuccilli M, Saragoni S, Cinti Luciani A, Degli Esposti L
ClinicoEconomics and Outcomes Research 2025, 17:147-155
Published Date: 6 March 2025
Dose Escalation Patterns and Associated Costs of Advanced Therapies for Ulcerative Colitis in France and the United Kingdom: A Retrospective Database Analysis
Treuer T, Richards M, Mert C, Dhesi E, Silva L, Tan Y, Hoque S
ClinicoEconomics and Outcomes Research 2025, 17:129-146
Published Date: 1 March 2025
Sensitivity of Cost-Effectiveness to Inclusion of Adverse Drug Events: A Scoping Review of Economic Models of Pharmacological Interventions for Diabetes, Diabetic Retinopathy, and Diabetic Macular Edema
Pesonen M, Kankaanpää E
ClinicoEconomics and Outcomes Research 2025, 17:115-128
Published Date: 26 February 2025
Using QIP-MS to Guide the Timing of MRD Testing in Patients With Multiple Myeloma: A Budget Impact Analysis From the French Payer Perspective
Siegfried C, Amarapala M, Leleu X, Fusfeld L
ClinicoEconomics and Outcomes Research 2025, 17:107-114
Published Date: 20 February 2025
Budget Impact and Cost–Benefit Analyses of Sodium-Glucose Cotransporter-2 Inhibitors for Patients With Heart Failure in Thailand
Arunmanakul P, Phodha T, Pinta-ay S, Nimworapan M, Phrommintikul A, Thammatacharee N, Dilokthornsakul P
ClinicoEconomics and Outcomes Research 2025, 17:95-105
Published Date: 17 February 2025
Real World Evaluation of Next-Day Molecular Respiratory Infectious Disease Testing on Healthcare Resource Utilization and Costs
French AJ, Fragala MS, Evans AS, Upadhyay P, Goldberg SE, Reddy J
ClinicoEconomics and Outcomes Research 2025, 17:79-93
Published Date: 11 February 2025
Atopic Dermatitis Treatments Before and After Initiation of Ruxolitinib Cream: 6-Month Follow-Up Analysis of a US Payer Claims Database
Liu J, Desai K, Teng CC, Sturm D, Stockbower G, Patadia H, Willey V
ClinicoEconomics and Outcomes Research 2025, 17:69-77
Published Date: 6 February 2025
Estimating the Cost-Effectiveness of Tumor Treating Fields (TTFields) Therapy with an Immune Checkpoint Inhibitor or Docetaxel in Metastatic Non-Small Cell Lung Cancer
Furnback W, Wu E, Koh CYC, Nino de Rivera Guzman JF, Kruhl C, Kotecha R, Wang BC
ClinicoEconomics and Outcomes Research 2025, 17:55-68
Published Date: 5 February 2025
Financial Cost of Treating Polytrauma in a Public Tertiary Hospital in the South-Eastern Democratic Republic of Congo: A Case Series Study
Kabeya Diyoka C, Ngongo Mwanvua L, Shauri Kalemera M, Pambi Mukanga P, Koba Mjumbe C
ClinicoEconomics and Outcomes Research 2025, 17:45-54
Published Date: 4 February 2025
Cost-Benefit Analysis of Genetic Testing as a Prenatal Diagnostic Tool for Thalassemia: A Single-Center Study From Central Thailand
Malasai K, Jittikoon J, Udomsinprasert W, Talungchit P, Youngkong S, Sangroongruangsri S, Mahasirimongkol S, Chaikledkaew U
ClinicoEconomics and Outcomes Research 2025, 17:33-43
Published Date: 4 February 2025
The Comparison of Cost-Effectiveness Between Magnetic Resonance Spectroscopy and Provocative Discography in the Identification of Chronic Low Back Pain Surgery Candidates
Wilson L, Beall DP, Eastlack RK, Berven S, Lotz JC
ClinicoEconomics and Outcomes Research 2025, 17:19-31
Published Date: 23 January 2025
A Novel Model Using ML Techniques for Clinical Trial Design and Expedited Patient Onboarding Process
Iyer A, Narayanaswami S
ClinicoEconomics and Outcomes Research 2025, 17:1-18
Published Date: 16 January 2025